Comparison

Motolimod European Partner

Item no. HY-13773-10mg
Manufacturer MedChem Express
CASRN 926927-61-9
Amount 10 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 1 g 1 mg 250 mg 25 mg 500 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 98.98
Citations [1]Lu H, et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res. 2012 Jan 15;18(2):499-509.|[2]Dietsch GN, et al. Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity. PLoS One. 2016 Feb 29;11(2):e0148764.
Smiles O=C(C1=CC2=CC=C(C3=CC=C(C(N4CCCC4)=O)C=C3)C=C2N=C(N)C1)N(CCC)CCC
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias VTX-2337,VTX-378
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
Cancer-programmed cell death
Manufacturer - Targets
Toll-like Receptor (TLR)
Shipping Temperature
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight
458.60
Product Description
Motolimod (VTX-2337; VTX-378) is a selective Toll-like receptor 8 (TLR8) agonist, with an EC50 of approximately 100 nM.
Manufacturer - Research Area
Cancer
Solubility
DMSO: 50 mg/mL (ultrasonic)
Manufacturer - Pathway
Immunology/Inflammation
Isoform
TLR8
Clinical information
Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close